Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Wixela inhaler cost?

See the DrugPatentWatch profile for Wixela

Wixela Inhub (the generic inhaler for Advair Diskus) price varies a lot by country, strength, and whether you have insurance.

rough guidance for the US:
- List price for a 60-dose inhaler (typical strength 250/50 or 500/50) often falls roughly in the $350–$550 range without insurance.
- With most private insurance or Medicare plans, your out-of-pocket is usually much lower, commonly around $20–60 per month, depending on your plan.
- Cash prices via discount programs (e.g., GoodRx) can be lower, but exact amounts vary.

If you want, I can help you estimate based on:
- your country or region
- the exact strength (e.g., 250/50 or 500/50)
- whether you have insurance and what your plan covers

Tips to save on cost:
- Check the cash price at local pharmacies and compare with GoodRx or other discount programs.
- Ask your prescriber if a generic is available and if your insurer covers Wixela Inhub as a preferred option.
- In some cases, there are patient assistance programs or coupons from the manufacturer or the generic sponsor.

Let me know your country, strength, and insurance status and I can tailor the guidance or help you find current prices at nearby pharmacies.



Other Questions About Wixela :

wixela 100/50 Wixela inhaler cost without insurance? Wixela 500 50 price? Wixela manufacturer coupon? Wixela vs trelegy? Wixela price per unit? Wixela inhub 100/50?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Unknown

Summary

Unable to perform label-alignment evaluation of an AI-generated prescribing-information response because no clear, single AI response content is provided to assess against the supplied FDA label. The provided text appears to be an analysis/citation summary, not a prescribing-information claim to verify.


Category Scores


Accurate Statements


Unsupported Statements

“The label explicitly states Wixela Inhub® is NOT indicated for the relief of acute bronchospasm ... The label also states that extra doses or increased frequency are not recommended, and that patients should not use additional LABA therapy.”
No explicit AI-generated prescribing-information claims beyond your pasted label excerpts can be verified as being made by an AI response. This appears to be label assessment text rather than a directly evaluable AI response claim.
“Contradicted: yes / Supported: yes / Evidence Summary ...”
These are meta-claims about support/contradiction, but there is no distinct AI response statement being evaluated against the label.

Contradictions


Important Omissions

The actual AI-generated response text containing the claims to be evaluated (e.g., an answer given by the AI to a user question).
Importance: High

Safety Assessment

Potential Patient Risk: Unknown
Cannot assess whether the supposed AI response would lead to incorrect clinical use because the evaluable AI response content is not provided as a clear set of claims.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Evaluated

Primary Issue
No discrete AI-generated prescribing/label-claim response provided for evaluation against the supplied FDA label.

Suggested Improvement
Provide the exact AI-generated answer text (the claims to evaluate). Then I can score alignment for indication, dosage, contraindications, warnings (including not for acute bronchospasm/rescue), interactions, populations, adverse reactions, and administration/storage where applicable.